Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma

Cell Death Dis. 2022 Jan 24;13(1):80. doi: 10.1038/s41419-022-04526-0.

Abstract

Glioblastoma (GBM) is the most lethal brain tumor in adults. Radiation, together with temozolomide is the standard treatment, but nevertheless, relapse occurs in nearly all cases. Understanding the mechanisms underlying radiation resistance may help to find more effective therapies. After radiation treatment, ATP is released into the tumor microenvironment where it binds and activates purinergic P2 receptors, mainly of the P2X7 subtype. Two main P2X7 splice variants, P2X7A and P2X7B, are expressed in most cell types, where they associate with distinct biochemical and functional responses. GBM cells widely differ for the level of P2X7 isoform expression and accordingly for sensitivity to stimulation with extracellular ATP (eATP). Irradiation causes a dramatic shift in P2X7 isoform expression, with the P2X7A isoform being down- and the P2X7B isoform up-modulated, as well as extensive cell death and overexpression of stemness and senescence markers. Treatment with P2X7 blockers during the post-irradiation recovery potentiated irradiation-dependent cytotoxicity, suggesting that P2X7B activation by eATP generated a trophic/growth-promoting stimulus. Altogether, these data show that P2X7A and B receptor isoform levels are inversely modulated during the post-irradiation recovery phase in GBM cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate* / metabolism
  • Glioblastoma* / genetics
  • Glioblastoma* / metabolism
  • Glioblastoma* / radiotherapy
  • Humans
  • Neoplasm Recurrence, Local
  • Protein Isoforms / genetics
  • Protein Isoforms / metabolism
  • Receptors, Purinergic P2X7* / genetics
  • Tumor Microenvironment

Substances

  • Protein Isoforms
  • Receptors, Purinergic P2X7
  • Adenosine Triphosphate